DEAR DR. DONOHUE: My grandson has had cluster headaches for at least one year. He has taken several medications and treatments. Nothing has helped. Can you give me any advice for this? - A.M.

Surgery early on to treat sciatica relieves pain more quickly than nonsurgical treatments, according to a study in the May 31 New England Journal of Medicine. But almost all people with sciatica had recovered completely a year later, whether they had surgery or not. Sciatica, pain that radiates down the back into one leg, is caused by a protruding disk in the lower spinal column that presses on ...

Surgery is a valid choice for people who suffer back and leg pain caused by two common ailments in older people, spinal stenosis and spondylolisthesis, according to a study in the May 31 New England Journal of Medicine.

A new study finds that surgery is often the fastest way to end back and leg pain, but waiting works as well.

People who suffer from chronic pain may find their memory taxed by everyday "multitasking," a new study suggests.

Not long ago, choosing a pain reliever meant finding one that eased your pain without being too hard on the stomach. Now, research suggests that some commonly used pain medications -- not just the now-banned Vioxx -- can raise the risk of having a heart attack or stroke. New step-by-step recommendations from the American Heart Association (AHA) can help you choose a pain reliever that's good for ...

Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the U.S.

Progenics Pharmaceuticals, ( Nachrichten ) Inc. (NASDAQ: PGNX) and Wyeth ( Nachrichten ) Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the U.S. Food and Drug Administration (FDA) has accepted the file for review of Progenics ' New Drug Application (NDA) for subcutaneous methylnaltrexone for the treatment of opioid-induced constipation (OIC) in patients receiving ...

TARRYTOWN, N.Y., & COLLEGEVILLE, Pa.----Progenics Pharmaceuticals, Inc. and Wyeth Pharmaceuticals, a division of Wyeth , announced today that the U.S. Food and Drug Administration has accepted the file for review of Progenics' New Drug Application for subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients receiving palliative care.

Jazz Pharmaceuticals Inc., a drug company that specializes in treatments for neurological and psychiatric conditions, lowered the expected price range of its initial public offering, according to a regulatory filing Thursday with the Securities and Exchange Commission.